Table 1 Candidate genes whose expression is altered in the cancer stem cell population
Gene description | Symbol | Stem versus committed* | Malignant versus benign* |
|---|---|---|---|
Pregnancy-associated plasma protein A, pappalysin 1 | PAPPA | 3.83 | 3.26 |
Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105) | NFKB1 | 2.30 | 1.86 |
Tight junction protein 2 (zona occludens 2) | TJP2 | 2.51 | 1.72 |
Abl-interactor 1 | ABI1 | 3.41 | 1.84 |
B-cell translocation gene 1, anti-proliferative | BTG1 | 3.95 | 1.53 |
Interleukin 6 (interferon, beta 2) | IL6 | 1.93 | 5.18 |
CASP8 and FADD-like apoptosis regulator | CFLAR | 1.90 | 1.41 |
Smu-1 suppressor of mec-8 and unc-52 homolog (C. elegans) | SMU1 | 1.90 | 1.63 |
S100 calcium binding protein A3 | S100A3 | 1.92 | 1.55 |
Chromosome 17 open reading frame 27 | C17orf27 | 1.63 | 1.80 |
RAS and EF-hand domain containing | RASEF | 2.31 | 1.71 |
Integrin, alpha V (vitronectin receptor, alpha polypeptide, antigen CD51) | ITGAV | 2.55 | 1.62 |
Interferon gamma receptor 1 | IFNGR1 | 1.70 | 1.46 |
Insulin growth factor-like family member 1 | IGFL1 | -1.17 | -28.61 |
Microseminoprotein, beta- (PSP94) | MSMB | -27.78 | -2.84 |
Prostate stem cell antigen | PSCA | -20.11 | -2.27 |
Carcinoembryonic antigen-related cell adhesion molecule 5 | CEACAM5 | -19.12 | -1.77 |
S100 calcium binding protein A7 (psoriasin 1) | S100A7 | -11.48 | 2.28 |
Hydroxyprostaglandin dehydrogenase 15-(NAD) | HPGD | -8.54 | -2.41 |
Carcinoembryonic antigen-related cell adhesion molecule 7 | CEACAM7 | -19.22 | 2.95 |
Trefoil factor 1 (breast cancer, estrogen-inducible sequence expressed in) | TFF1 | -11.74 | -2.25 |
Prolactin-induced protein | PIP | -17.42 | 1.04 |